PIH32 - INNOVATIVE PAYMENT MECHANISM: SOLVING INEQUITIES FOR HER2 (-) BREAST CANCER CASES IN CHILE.
نویسندگان
چکیده
منابع مشابه
Optimization of Real Time PCR for Precise Measurement of HER2 Overexpression in Breast Cancer Specimens
Background: Breast cancer is one of the most prevalent malignancies among women in various countries. HER2 overexpression, which is due to different reasons, occurs in 20-30% of breast cancers. HER2 gene encodes an 185kDa transmembrane glycoprotein with 1255 amino acids. This active product triggers downstream intracellular signaling pathways inducing cell proliferation and cell survival. These...
متن کاملGeneration of CHO Stable Cell Line Overexpressing HER2: an In Vitro Model for Breast Cancer
Background: Breast cancer is the most common female malignancy and the leading cause of cancer mortality in women worldwide. The human epidermal growth factor receptor2 (HER2) is a transmembrane tyrosine kinase receptor that is usually overexpressed in human breast cancers. Stable cell lines heterogeneously overexpressing HER2 are highly required as in vitro models for breast cancer research. T...
متن کاملHER2-Positive Breast Cancer
• Objective: To review the diagnosis and management of HER2-positive breast cancer. • Methods: Qualitative review of the literature. • Results: Amplification of HER2 occurs in 20% to 25% of breast cancers and is associated with highgrade tumors that are poorly differentiated and have higher rates of recurrence. Trastuzumab, a recombinant humanized monoclonal antibody against the extracellular d...
متن کاملHER2-Specific Vaccines for HER2-Positive Breast Cancer Immunotherapy
Anti-human epidermal growth factor receptor-2 (HER2) immunization can be elicited by vaccination with DNA encoding the extraor intra-cellular domain (ECD or ICD) of HER2, naked or encapsulated in viral vectors. HER2-peptides derived from ECD or ICD of HER2, and HER2-pulsed dendritic cells (DCs) or engineered DCs expressing HER2, respectively. We performed a computerbased literature search which...
متن کاملHER2-directed therapy for metastatic breast cancer.
Human epidermal growth factor receptor 2 (HER2) overexpression drives the biology of 20% of breast cancers, and predicts a poor prognosis for patients. HER2-targeted therapies significantly improve outcomes for HER2-positive patients with both early and metastatic breast cancer. Currently three HER2-targeted agents, trastuzumab (Herceptin), lapatinib (Tykerb), and pertuzumab (Perjeta), are avai...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2018
ISSN: 1098-3015
DOI: 10.1016/j.jval.2018.09.1297